Dr. Joan Carles  Galceran

Dr. Joan Carles Galceran

Address: Carrer de Vilana, 12, 08022 Barcelona, Barcelona, Catalunya, Spain

Gender: Male

Type of Professional: Oncologist

Associated Healthcare Provider: QS Teknon Medical Center

Languages Spoken: Spanish

About the Doctor / Professional

Dr. Joan Carles Galceran is the Chief Specialist of the Oncology Institute Teknon in the field of treatment of sarcomas, melanomas and oncology of genitourinary system. 

He graduated in Medicine and Surgery from the University of Barcelona in 1987 and received his doctorate, laude, in 1992 from the Autonomous University of Barcelona. He completed his residency in Medical Oncology at the Germans Trias i Pujol University Hospital in Badalona. He completed his training by obtaining the European Certificate in Medical Oncology in Vienna in November 1996.

After completing his residency, he joined the Medical Oncology Service of the Hospital de Terrassa (from June 1991 to April 1992). Subsequently, he joined the Medical Oncology Service of the Hospital del Mar in Barcelona until September 2008. From this date he joined the Department of Oncology of the Vall d'Hebron University Hospital as Head of Section and Coordinator of the Genitourinary, Central Nervous System, Sarcomas and Unknown Origin Unit.

Dr. Joan Carles Galceran is co-founder, secretary of the Spanish Group for the Treatment of Genetic-Urinary Tumors (SOGUG), in which he has served as Secretary and Vice-President. He has been an associate professor of Medicine at the Autonomous University of Barcelona since 1995 and responsible for the elective subject of Medical Oncology. He is currently an Associate Professor at the International University of Catalonia. Dr. Joan Carles has published more than 120 peer-reviewed articles and more than 350 conference papers and book chapters.

His areas of interest are genito-urinary clinical oncology, sarcomas, and early and translational clinical research in the field of genetic polymorphisms and angiogenesis, among others, as targets in cancer therapy. He leads national multicenter trials of new drugs in the treatment of prostate, kidney, and bladder cancer.